Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential

Current Topics in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 396-415

  Zuliani, Valentina ^a   Patel, Manoj K ^b   Fantini, Marco ^a   Rivara, Mirko ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Blockers; Epilepsy; Nav isoforms; Pain; Sodium channels

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 4 PHENYLIMIDAZOLE; ARYLPYRAZINE DERIVATIVE; BENZAZEPINONE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOTHIAZEPINONE DERIVATIVE; BENZOXATHIEZEPINE DERIVATIVE; BENZOXAZEPINONE DERIVATIVE; BIPHENYLPYRAZINONE DERIVATIVE; CARBAMAZEPINE; DIPHENYLAMINE; FURAN GLYCINAMIDE; HYDANTOIN DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; LICARBAZEPINE; LIDOCAINE; PHENETHYLAMINE DERIVATIVE; PHENYLFURAN DERIVATIVE; PHENYLPYRROLIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDOPYRIMIDINONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RALFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; SPIROINDOLE DERIVATIVE; TETRODOTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROBIC METABOLISM; ANTICONVULSANT ACTIVITY; CHRONIC PAIN; DEGENERATIVE DISEASE; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; DRUG INACTIVATION; DRUG INDICATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; EPILEPSY; EXCITABILITY; HEART ARRHYTHMIA; HUMAN; IC 50; IRRITABLE COLON; ISCHEMIA; MIGRAINE; NEUROPATHIC PAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; REVIEW; SPASTICITY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

EID: 66449110564     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788317856     Document Type: Review

References (165)

1. Goldin, A. L. Resurgence of Sodium Channel Research. Annu. Rev. Physiol. 2001, 63, 871-894.
2. Isom, L.L.; De Jongh, K.S.; Patton, D.E.; Reber, B.F.; Offord, J.; Charbonneau, H.; Walsh, K.; Goldin, A.L.; Catterall, W.A. Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. Science 1992, 256, 839-842
3. Isom, L.L.; Ragsdale, D.S.; De Jongh, K.S.; Westenbroek, R.E.; Reber, B.F.; Scheuer, T.; Catterall, W.A. Structure and function of the beta 2 subunit of brain sodium Channels, a Transmembrane Glycoprotein with a CAM Motif. Cell 1995, 83, 433-442.
4. Morgan, K.; Stevens, E.B.; Shah, B.; Cox, P.J.; Dixon, A.K.; Lee, K.; Pinnock, R.D.; Hughes, J.; Richardson, P.J.; Mizuguchi, K.; Jackson, A.P. Beta 3: An Additional Auxiliary Subunit of the Voltage-sensitive Sodium Channel that Modulates Channel Gating with Distinct Kinetics. Proc. Natl. Acad. Sci. USA 2000, 97, 2308- 2313.
5. Yu, F.H.; Westenbroek, R.E.; Silos-Santiago, I.; McCormick, K.A.; Lawson, D.; Ge, P.; Ferriera, H.; Lilly, J.; DiStefano, P.S.; Catterall, W.A.; Scheuer, T.; Curtis, R. Sodium Channel Beta 4, a New Disulfide-linked Auxiliary Subunit with Similarity to Beta 2. J. Neurosci. 2003, 23, 7577-7585.
6. Stühmer, W.; Conti, F.; Suzuki, H.; Wang, X.; Noda, M.; Yahagi, N.; Kubo, H.; Numa, S. Structural Parts Involved in Activation and Inactivation of the Sodium Channel. Nature 1989, 339, 597-603.
7. Yang, N.; George, A.L.J.; Horn, R. Molecular Basis of Charge Movement in Voltage-gated Sodium Channels. Neuron 1996, 16, 113-122.
8. Heinemann, S.H.; Terlau, H.; Stuhmer, W.; Imoto, K.; Numa, S. Calcium Channel Characteristics Conferred on the Sodium Channel by Single Mutations. Nature 1992, 356, 441-443.
9. West, J.W.; Patton, D.E.; Scheuer, T.; Wang, Y.; Goldin, A.L.; Catterall, W.A. A Cluster of Hydrophobic Amino Acid Residues Required for Fast Na(+)-channel Inactivation. Proc. Natl. Acad. Sci. USA 1992, 89, 10910-10914.
10. O'Reilly, J.P.; Wang, S.Y.; Wang, G.K. Residue-specific Effects on Slow Inactivation at V787 in D2-S6 of Na(v)1.4 Sodium Channels. Biophysical. J. 2001, 81, 2100-2111.
11. + Channel Slow Inactivation via cAMP-dependent Protein Kinase and Protein Kinase C. Neuron 2006, 49, 409-420.
12. Tarnawa, I.; Bölcskei, H.; Kocsis, P. Blockers of Voltage-gated Sodium Channel for the Treatment of Central Nervous System Diseases. Recent Pat. CNS Drug Discov. 2007, 2, 57-78.
13. Bölcskei, H.; Tarnawa, I.; Kocsis, P. Voltage-gated sodium channel blockers, 2001-2006: An Overview. Med. Chem. Res. 2008, 17, 356-368.
14. Chakravarty, P.K.; Fisher, M.H.; Parsons, W.H.; Liang, J.; Zhou, B. Biaryl Substituted 6-Membered Heterocycles as Sodium Channel Blockers. World Pat. Apl. 084824, Oct 7, 2004.
15. Chakravarty, P.K.; Fisher, M.H.; Palucki, B.; Park, M.K.; Parsons, W.H.; Zhou, B.; Carey, J.P.; Frantz, D.E.; Kress, M.H.; Weaver, D. Biaryl substituted triazoles as sodium channel blockers. World Pat. Apl. 083190, Sep 30, 2004.
16. Chakravarty, P.K.; Fisher, M.H.; Palucki, B.; Park, M.K.; Parsons, W.H.; Zhou, B.; Carey, J.P.; Frantz, D.E.; Kress, M.H.; Weaver, D. Biaryl Substituted Triazoles as Sodium Channel Blockers. World Pat. Apl. 083189, Sep 30, 2004.
17. Chakravarty, P.K.; Fisher, M.H.; Parsons, W.H.; Tyagarajan, S.; Zhou, B. Biaryl Substituted Pyrazoles as Sodium Channel Blockers. World Pat. Apl. 092140, Oct 28, 2004.
18. Chakravarty, P.K.; Fisher, M.H.; Parsons, W.H.; Tyagarajan, S.; Zhou, B. Biaryl Substituted Thiazoles, Oxazoles and Imidazoles as Sodium Channel Blockers. World Pat. Apl. 094395, Nov 4, 2004.
19. Park, M.K.; Chakravarty, P.K.; Zhou, B.; Gonzales, E.; Ok, H.; Palucki, B.; Parsons, W.H.; Sisco, R.; Fisher, M.H. Substituted Triazoles as Sodium Channel Blockers. World Pat. Apl. 047270, May 26, 2005.
20. Liang, J.; Chakravarty, P.K.; Pan, D.E.; Parsons, W.H.; Shao, P.P.; Yee, F.; Zhou, B. Biaryl Substituted Pyrazinones as Sodium Channel Blockers. World Pat. Apl. 097136, Oct 20, 2005.
21. Chakravarty, P.K.; Fisher, M.H.; Parsons, W.H.; Liang, J.; Zhou, B. Biaryl Substituted 6-Membered Heterocycles as Sodium Channel Blockers. US. Pat. Apl. 0293339, Dec 28, 2006.
22. Chakravarty, P.K.; Fisher, M.H.; Parsons, W.H.; Palucki, B.; Zhou, B.; Park, M.K. Biaryl Substituted Triazoles as Sodium Channel Blockers. US. Pat. Apl. 0171777, Jul 17, 2008.
23. Liberatore, A.-M.; Schulz, J.; Pommier, J.; Barthelemy, M.-A.; Huchet, M.; Chabrier, P.-E.; Bigg, D. 2-Alkyl-4-arylimidazoles: Structurally Novel Sodium Channel Modulators. Bioorg. Med. Chem. Lett. 2004, 14, 3521-3523.
24. Chabrier, P.-E.; Harnett, J.; Bigg, D.; Liberatore, A.-M.; Thurieau, C.; Dong, Z.X. Derivatives of 4-Phenylthiazoles and 4-Phenylimidazoles and the Use thereof as Medicaments for Treating Neurodegenerative Diseases, Pain and Epilepsy. World Pat. Apl. 035510, Apr 21, 2005.
25. Liberatore, A.-M.; Schulz, J.; Favre-Guilmard, C.; Pommier, J.; Lannoy, J.; Pawlowski, E.; Barthelemy, M.-A.; Huchet, M.; Auguet, M.; Chabrier, P.-E.; Bigg, D. Butyl 2-(4-[1.1′-biphenyl] -4-yl-1H-imidazol-2-yl)ethylcarbamate, a Potent Sodium Channel Blocker for the Treatment of Neuropatic Pain. Bioorg. Med. Chem. Lett. 2007, 17, 1746-1749.
26. Rivara, M.; Baheti, A.R.; Fantini, M.; Cocconcelli, G.; Ghiron, C.; Kalmar, C.L.; Singh, N.; Merrick, E.C.; Patel, M.K.; Zuliani, V. 2,4(5)-Diarylimidazoles: Synthesis and Biological Evaluation of a New Class of Sodium Channel Blockers against hNaV1.2. Bioorg. Med. Chem. Lett. 2008, 18, 5460-5462.
27. Zuliani, V.; Cocconcelli, G.; Fantini, M.; Ghiron, C.; Rivara, M. A Practical Synthesis of 2,4(5)-Diarylimidazoles from Simple Building Blocks. J. Org. Chem. 2007, 72, 4551-4553.
28. Gibson, K.R.; Poinsard, C.; Glossop, M.S.; Kemp, M.I. Pyrazine Derivatives. World Pat. Apl. 052123, May 10, 2007.
29. Alvaro, G.; Bergauer, M.; Giovannini, R.; Profeta, R. Prolinamide Derivatives as Sodium Channel Modulators. World Pat. Apl. 042239, Apr 19, 2007.
30. Daniel, S.; Malkowitz, L.; Wang, H.-C.; Beer, B.; Blume, A.J.; Ziai, M.R. Screening for Potassium Channel Modulators by a High Through-put 86-Rubidium Efflux Assay in a 96-Well Microtiter Plate. J. Pharmacol. Methods 1991, 25, 185-193.
31. Worley, J.F.; Main, M.J. An Industrial Perspective on Utilizing Functional Ion Channel Assay for High Throughput Screening. Recept. Channels 2002, 8, 269-282.
32. V1.8 Sodium Channel with Efficacy in Models of Neuropathic and Inflammatory Pain. J. Med. Chem. 2008, 51, 407-416.
33. V1.8 Sodium Channel Blocker, Attenuates Neuropathic and Inflammatory Pain in the Rat. Proc. Natl. Acad. Sci. USA 2007, 104, 8520-8525.
34. Drizin, L.; Gregg, R.; Scanio, M.; Shi, L.; Gross, M.; Atkinson, R.N.; Thomas, J.B.; Johnson, M.S.; Carrol, W.A.; Marron, B.E.; Chapman, M.L.; Liu, D.; Krambis, M.J.; Shieh, C.C.; Zhang, X.; Hernandez, G.; Gauvin, D.M.; Mikusa, J.P.; Zhu, C.Z.; Joshi, S.; Honore, P.; Marsh, K.C.; Roeloffs, R.; Werness, S.; Krafte, D.S.; Jarvis, M.F.; Faltynek, C.R.; Kort, M.E. Discovery of Potent Furan Piperazine Sodium Channel Blockers for Treatment of Neuropathic Pain. Bioorg. Med. Chem. 2008, 16, 6379-6386.
35. Hoyt, S.B.; London, C.; Ok, D.; Parsons, W.H. Benzazepinones as Sodium Channel Blockers. World Pat. Apl. 145922, Dec 21, 2007.
36. v1.7 Blockers: Potential Treatments for Neuropathic Pain. Bioorg. Med. Chem. Lett. 2007, 17, 4630-4634.
37. v1.7 Blockers: Potential Treatments for Neuropathic Pain. Bioorg. Med. Chem. Lett. 2007, 17, 6172-6177.
38. Hoyt, S.B.; London, C.; Wyvratt, M.J.; Fisher, M.J.; Cashen, D.E.; Felix, J.P.; Garcia, M.L.; Li, X.; Lyons, K.A.; MacIntyre, D.E.; Martin, W.J.; Priest, B.T.; Smith, M.M.; Warren, V.A.; Williams, B.S.; Kaczorowsky, G.J.; Parsons, W.H. 3-Amino-1,5-benzodiazepinones: Potent, State-dependent Sodium Channel Blockers with Anti-epileptic Activity. Bioorg. Med. Chem. Lett. 2008, 18, 1963-1966.
39. Hoyt, S.B.; Ok, D.; Hyun, O.; London, C.; Duffy, J.L. Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers. World Pat. Apl. 106077, Sep 4, 2008.
40. Le Grand, B.; Pignier, C.; Létienne, R.; Cuisiat, F.; Rolland, F.; Mas, A.; Vacher B. Sodium Late Current Blockers in Ischemia Reperfusion: Is the Bullet Magic? J. Med. Chem. 2008, 51, 3856-3866.
41. Vacher, B.; Castan-Cuisiat, F.; John, G.; Le Grand, B. Benzoxathiepin Derivatives and Their Use in Medicines. World Pat. Apl. 081464, Oct 17, 2002.
42. Pignier, C.; Letienne, R.; Vacher, B.; Delhon, A.; Le Grand, B. Antiischemic Activities of F15845, a New Blocker of the Persistent Cardiac Sodium Current. Acta Pharmacol. Sinica 2006, 27 169.
43. Pignier, C.; Letienne, R.; Vacher, B.; Delhon, A.; Le Grand, B. F15845: a Voltage-dependent Persistent Sodium Current Blocker. Eur. Heart J. 2006, 27, S1.
44. DiFrancesco, D.; Camm, J.A. Heart Rate Lowering by Specific and Selective If Current Inhibition with Ivabradine. A New Therapeutic Perspective in Cardiovascular Disease. Drugs 2004, 64, 1757-1765.
45. Ruzyllo, W.; Tendera, M.; Ford, L.; Fox, K.M. Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris. Drugs 2007, 67, 393-405
46. Gibson, K.R.; Glossop, M.S. Pyridine Derivatives as Sodium Channel Modulators. World Pat. Apl. 083239, Jul 26, 2007.
47. Johnson, C.N.; Macpherson, D.T.; Trani, G. Pyridine Derivatives as Sodium Channel Blockers. World Pat. Apl. 017691, Feb 14, 2008.
48. V1.7 Channel Blockers. Bioorg. Med. Chem. Lett. 2008, 18, 1696-1701.
49. Liu, S.; Fu, J.; Kamboj, R.; Chowdhury, S.; Jia, Q.; Wood, M.; Sun, J. Pyridopyrimidinone Compounds Useful in Treating Sodium Channel-Mediated Diseases or Conditions. US. Pat. Apl. 0194616, Aug 14, 2008.
50. Hardman, J.G.; Limbrid, L.E.; Gilman, A.G. Goodman and Gilman's Pharmacological Basis of therapeutics, 10th ed. New York; McGraw Hill, 2001.
51. Brouilette, W.J.; Jetkov, V.P.; Brown, M.L.; Akhtar, M.S.; DeLorey, M.T.; Brown, G.B. Bicyclic Hydantoins with a Bridgehead Nitrogen. Comparison of Anticonvulsant Activities with Binding to the Neuronal Voltage-Dependent Sodium Channel. J. Med. Chem. 1994, 37, 3289-3293.
52. Brown, M.L.; Brown, G.B.; Brouillette, W.J. Effect of log P and Phenyl Ring Conformation on the Binding of 5-Phenylhydantoins to the Voltage-Dependent Sodium Channel. J. Med. Chem. 1997, 40, 602-607.
53. Lenkowsky, P.W.; Batts, T.W.; Smith, M.D.; Ko, S.-H.; Jones, P.J.; Taylor, C.H.; McCusker, A.K.; Davis, G.C.; Hartmann, H.A.; White, H.S.; Brown, M.L.; Patel, M.K. A Pharmacophore Derived Phenytoin Analogue with Increase Affinity for Slow Inactivated Sodium Channels Exhibits a Desired Anticonvulsant Profile. Neuropharmacol. 2007, 52, 1044-1054.
54. Brown, M.L.; Zha, C.C.; Van Dyke, C.C.; Brown, G.B.; Brouillette, W.J. Comparative Molecular Field Analysis of Hydantoin Binding to the Neuronal Voltage-Dependent Sodium Channel. J. Med. Chem. 1999, 42, 1537-1545.
55. Wang, Y.; Jones, P.J.; Batts, T.W.; Landry, V.; Patel, M.K.; Brown, M.L. Ligand Based Design and Synthesis of Novel Sodium Channel from a Combined Phenytoin-Lidocaine Pharmacophore. Bioorg. Med. Chem. 2009, doi: 10.1016/j.bmc.2008.10.031 [Epub ahead of print]
56. Brown, M.L. Novel Tricyclic, Bicyclic, Monocyclic and Acyclic Amines as Potent Sodium Channel Blocking Agents. World Pat. Apl., 023757, Mar 2, 2006.
57. v1.2. Bioorg. Med. Chem. 2006, 14, 8366-8378.
58. 3H]Batrachotoxinin A 20.alpha.-benzoate Binding to Voltage-sensitive Sodium Channels: A Rapid and Quantitative Assay for Local Anesthetic Activity in a Variety of Drugs. J. Med. Chem. 1985, 28, 381-388.
59. Amir, R.; Argoff, C.E.; Bennett, G.J.; Cummins, T.R.; Durieux, M.E.; Gerner, P.; Gold, M.S.; Porreca, F.; Strichartz, G.R. The Role of Sodium Channels in Chronic Inflammatory and Neuropathic Pain. J. Pain 2006, 7, S1-29.
60. + Channels by Amitriptyline via the Local Anesthetic Receptor and its Implication for Neuropathic Pain. Pain 2004, 110, 166-174.
61. Cadieux, J.-J.; Chowdhury, S.; Fu, J.; Kamboj, R.; Hsieh, T.; Jia, Q.; Liu, S.; Sun, J. Spiro(furo[3,2-C]pyridine-3-3′-indol)-2′(1'H)-one Derivatives and Related Compounds for the Treatment of Sodium-channel Mediated Diseases, such as Pain. World Pat. Apl., 046049, Apr 17, 2008.
62. Barbanti, E.; Thaler, F.; Caccia, C.; Fardello, R.; Salvati, P. (Halobenzyloxy)benzylamino-propanamides as Sodium and/or Calcium Channel Selective Modulators. US Pat. Apl., 0096965, Apr 24, 2008.
63. Thaler, F.; Napoletano, M.; Sapido-David, C.; Moriggi, E.; Caccia, C.; Faravelli, L.; Restivo, A.; Salvati, P. 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators. World Pat. Apl. 071311, Jun 28, 2007.
64. Liu, S.; Sun, J.; Fraser, R.; Fu, J.; Kamboj, R.; Hou, D.; Sviridov, S. Quinazolinone and Fused Pyrimidinone Compounds and their Use in Treating Sodium Channel-mediated Diseases and Conditions. World Pat. Apl., 094909, Aug 7, 2008.
65. + Channels in Neurophatic Pain. Expert Opin. Investig. Drugs 2007, 16, 635-645.
66. Dickenson, A.H.; Matthews, E.A.; Suzuki, R. Neurobiology of Neuropathic Pain: Mode of Action of Anticonvulsants. Eur. J. Pain 2002, 6, 51-60.
67. Wood, J.N.; Boorman, J. Voltage-gated Sodium Channel Blockers; Target Validation and Therapeutic Potential. Curr. Top. Med. Chem. 2005, 5, 529-537.
68. + Channels in Pain Pathways. Trends Pharmacol. Sci. 2001, 22, 27-31
69. Amir, R.; Argoff, C.E.; Bennett, G.J.; The Role of Sodium Channels in Chronic Inflammatory and Neuropathic Pain. J. Pain 2006, 7, 1-29.
70. Waxman, S.G.; Kocsis, J.D.; Black, J.A. Type III Sodium Channel mRNA is Expressed in Embryonic but Not Adult Spinal Sensory Neurons, and is Reexpressed Following Axotomy. J. Neurophysiol. 1994, 72, 466-470.
71. Black, J.A.; Cummins, T.R.; Plumpton, C.; Chen, Y.H.; Hormuzdiar, W.; Clare, J.J.; Waxman, S.G. Upregulation of a Silent Sodium Channel after Peripheral, but Not Central, Nerve Injury in DRG Neurons. J. Neurophysiol. 1999, 82, 2776-2785.
72. Dib-Hajj, S.; Black, J.A.; Felts, P.; Waxman, S.G. Down-regulation of Transcripts for Na Channel Alpha-SNS in Spinal Sensory Neurons Following Axotomy. Proc. Natl. Acad. Sci. USA 1996, 93, 14950-14954.
73. Dib-Hajj, S.D.; Tyrrell, L.; Black, J.A.; Waxman, S.G. NaN, a Novel Voltage-gated Na Channel, is Expressed Preferentially in Peripheral Sensory Neurons and Down-regulated after Axotomy. Proc. Natl. Acad. Sci. USA 1998, 95, 8963-8968.
74. Kim, C.H.; Oh, Y.; Chung, J.M.; Chung, K. The Changes in Expression of Three Subtypes of TTX Sensitive Sodium Channels in Sensory Neurons after Spinal Nerve Ligation. Brain Res. Mol. Brain Res. 2001, 95, 153-161.
75. Cummins, T.R.; Waxman, S.G. Downregulation of Tetrodotoxin-resistant Sodium Currents and Upregulation of a Rapidly Repriming Tetrodotoxin-sensitive Sodium Current in Small Spinal Sensory Neurons after Nerve Injury. J. Neurosci. 1997, 17, 3503-3514.
76. Hains, B.C.; Klein, J.P.; Saab, C.Y.; Craner, M.J.; Black, J.A.; Waxman, S.G. Upregulation of Sodium Channel NaV1.3 and Functional Involvement in Neuronal Hyperexcitability Associated with Central Neuropathic Pain after Spinal Cord Injury. J. Neurosci. 2003, 23, 8881-8892.
77. Black, J.A.; Liu, S.; Tanaka, M.; Cummins, T.R.; Waxman, S.G. Changes in the Expression of Tetrodotoxin-sensitive Sodium Channels within Dorsal Root Ganglia Neurons in Inflammatory Pain. Pain 2004, 108, 237-247.
78. v1.3 Expression and Neuropathic Pain Behavior in Rats. Pain 2005, 117, 145-153.
79. v1.3 Null Mutant Mice. Mol. Pain. 2006, 2, 33.
80. Cummins, T.R.; Sheets, P.C.; Waxman, S.G. The Roles of Sodium Channel in Nociception: Implications for Mechanism of Pain. Pain 2007, 131, 243-257.
81. Krafte, D.S.; Bannon, A.V. Sodium Channels and Nociception: Recent Concepts and Therapeutic Opportunities. Curr. Opin. Pharmacol. 2008, 8, 50-56.
82. v1.3 Null Mutant Mice. Mol. Pain 2006, 2, 33.
83. Cox, J.J.; Reimann, F.; Nicholas, A.K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; AlGazali, L.; Hamamy, H.; Valente, E.M.; Gorman, S.; Williams, R.; McHale, D.P.; Wood, J.N.; Gribble, F.M.; Woods, C.G. An SCN9A Channelopathy Causes Congenital Inability to Experience Pain. Nature 2006, 444, 894-898.
84. Ahmad, S.; Dahllund, L.; Eriksson, A.B.; Hellgren, D.; Karlsson, U.; Lund, P.E.; Meijer, I.A.; Meury, L.; Mills, T.; Moody, A.; Morinville, A.; Morten, L.; O'donnell, D.; Raynoschek, C.; Salter, H.; Rouleau, G.A.; Krupp, J.J. A Stop Codon Mutation in SCN9A Causes Lack of Pain Sensation. Hum. Mol. Genet. 2007, 16, 2114-2121
85. Goldberg, Y.; Macfarlane, J.; Macdonald, M.; Thompson, J.; Dube, M.P.; Mattice, M.; Fraser, R.; Young, C; Hossain, S.; Pape, T.; Payne, B.; Radomski, C.; Donaldson, G.; Ives, E.; Cox, J.; Younghusband, H.B.; Green, R; Duff, A.; Boltshauser, E.; Grinspan, G.A.; Dimon, J.H.; Sibley, B.G.; Andria, G.; Toscano, E.; Kerdraon, J.; Bowsher, D.; Pimstone, S.N.; Samuels, M.E.; Sherrington, R.; Hayden, M.R. Loss-of-function Mutations in the Na(V)1.7 Gene Underlie Congenital Indifference to Pain in Multiple Human Populations. Clin. Genet. 2007, 71, 311-319.
86. Yang, Y.; Wang, Y.; Li, S.; Ma, L.; Fan, J.; Bu, D.; Liu, B.; Fan, Z.; Wu, G.; Jin, J.; Ding, B.; Zhu, X.; Shen, Y. Mutations in SCN9A, Encoding a Sodium Channel Alpha Subunit, in Patients with Primary Erythermalgia. J. Med. Genet. 2004, 41, 171-174
87. Chahine, M.; Ch'atelier, A.; Babich, O.; Krupp, J.J. Voltage-Gated Sodium Channels in Neurological Disorders. CNS Neurol. Disord. Drug 2008, 7, 144-158.
88. Harty, T.P.; Dib-Hajj, S.D.; Tyrell, L.; Blackman, R.; Hisama, F.M.; Rose, J.B.; Waxman, S.J. Nav1.7 Mutant A863P in Erythromelalgia: Effects of Altered Activation and Steady-State Inactivation on Excitability of Nociceptive Dorsal Root Ganglion Neurons. J. Neurosci. 2006, 26, 12566-12575.
89. Cummins, T.R.; Dib-Hajj, S.D.; Waxman, S.J. Electrophysiological Properties of Mutant Nav1.7 Sodium Channels in a Painful Inherited Neuropathy. J. Neurosci. 2004, 24, 8232-8236.
90. Fertleman, C.R.; Baker, M.D.; Parker, K.A.; Moffatt, S.; Elmslie, F.V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J.N.; Gardiner, R.M.; Rees, M. SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes. Neuron 2006, 52, 767-774.
91. Fertleman, C.R.; Ferrie, C.D.; Ai cardi, J.; Bednarek, N.A.; Eeg-Olofsson, O.; Elmslie, F.V.; Griesemer, D.A.; Goutières, F.; Kirkpatrick, M.; Malmros, I.N.; Pollitzer, M.; Rossiter, M.; Roulet-Perez, E.; Schubert, R.; Smith, V.V.; testard, H.; Wong, V.; Stephenson, J.B. Paroxysmal Extreme Pain Disorder (Previously Familial Rectal Pain Syndrome). Neurology 2007, 69, 586-595.
92. Momin, A.; Wood, J.N. Sensory Neuron Voltage-gated Sodium Channels as Analgesic Drug Targets. Curr. Opin. Neurobiol. 2008, 18, 1-6.
93. Khasar, S.G.; Gold, M.S.; Levine, J.D. A Tetrodotoxin-resistant Sodium Current Mediates Inflammatory Pain in the Rats. Neurosci. Lett. 1998, 256, 17-20.
94. Gold, M.S.; Weinreich, D.; Kim, C.S.; Wang, R.; Treanor, J.; Porreca, F.; Lai, L. Redistribution of NaV1.8 in Unijured Axons Enables Neuropathic Pain. J. Neurosci. 2003, 23, 158-166
95. Lai, J.; Gold, M.S.; Kim, C.S.; Bian, D.; Ossipov, M.H.; Hunter, J.C.; Porreca, F. Inhibition of Neuropathic Pain by Decreased Expression of the Tetrodotoxin-resistant Sodium Channel, NaV1.8. Pain 2002, 95, 143-152.
96. Akopian, A.N.; Sivilotti, L.; Wood, J.N. A Tetrodotoxin-resistant Voltage-gated Sodium Channel Expressed by Sensory Neurons. Nature 1996, 379, 257-262.
97. Dong, X.-W.; Goregoaker, S.; Engler, H.; Zhou, X.; Mark, L.; Crona, J.; Terry, R.; Hunter, J.; Priestley, T. Small Interesting RNA-mediated Selective Knockdown of NaV1.8 Tetrodotoxin-resistant Sodium Channel Reverses Mechanical Allodynia in Neuropathic Rats. Neuroscience 2007, 146, 812-821.
98. Novakovic, S.D.; Tzoumaka, E.; McGivern, J.G.; Haraguchi, M.; Sangameswaran, L.; Gogas, K.R.; Eglen, R.M.; Hunter, J.C. Distribution of the Tetrodotoxin-resistant Sodium Channel PN3 in Rat Sensory Neurons in Normal and Neuropathic Conditions. J. Neurosci. 1998, 18, 2174-2187.
99. Loscher, W.; Schmidt, D. New Horizons in the Development of Antiepileptic Drugs: The Search for New Targets. Epilepsy Res. 2004, 60, 77-159.
100. Remy, S.; Beck, H. Molecular and Cellular Mechanisms of Pharmacoresistance in Epilepsy. Brain 2006, 129, 18-35.
101. Brodie, M.J. Do We Need Any More New Antiepileptic Drugs? Epilepsy Res. 2001, 45, 3-6.
102. Meldrum, B.S.; Rogawski, M.A. Molecular Targets for Antiepileptic Drug Development. Neurotherapeutics 2007, 4, 18-61.
103. Rogawski, M.A.; Löscher, W. The Neurobiology of Antiepileptic Drugs. Nat. Rev. Neurosci. 2004, 5, 553-564.
104. Ketelaars, S.O.M.; Gorter, J.A.; van Vliet, E.A.; Lopes da Silva, F.H.; Wadman, W.J. Sodium Currents in Isolated Rat CA1 Pyramidal and Dentate Granule Neurones in the Post-status Epilepticus Model of Epilepsy. Neuroscience 2001, 105, 109-120.
105. + Channels Following Pilocarpine-induced Status Epilepticus in Rat Dentate Granule Cells. Neuroscience 2003, 119, 323-333.
106. Novakovic, S.D.; Tzoumaka, E.; McGivern, J.G.; Haraguchi, M.; Sangameswaran, L.; Gogas, K.R.; Eglen, R.M.; Hunter, J.C. Distribution of the Tetrodotoxin-resistant Sodium Channel PN3 in Rat Sensory Neurons in Normal and Neuropathic Conditions. J. Neurosci. 1998, 18, 2174-2187.
107. Kahlig, K.M.; Rhodes, T.H.; Pusch , M.; Freilinger, T.; Castro, M.J.; van den Maagdenberg, A.M.J.M.; Dichgans, M.; George, Jr., A.L. Plat Divergent Properties of NaV1.1 Mutations Associated with Familial Hemiplegic Migraine. Biophys. J. 2008, 94, 1866.
108. Freudiani, F. Anticonvulsant Drugs in Primary Headaches Prophylaxis. Neurol. Sci. 2004, 25, 161-166.
109. Saint, D.A. The Cardiac Persistent Sodium Current: An Appealing Therapeutic Target? Br. J. Pharmacol. 2008, 153, 1133-1142.
110. Zaza, A.; Belardinelli, L.; Shryock, J.C. Pathophysiology and Pharmacology of the Cardiac "Late Sodium Current". Pharm. Ther. 2008, 119, 326-339.
111. Phukan, J.; Pender, N.P.; Hardiman, O. Cognitive Impairment in Amyotrophic Lateral Sclerosis. Lancet Neurol. 2007, 6, 994-1003.
112. Compston, A.; Coles, A. Multiple Sclerosis. Lancet 2002, 359, 1221-1231.
113. Sakurai, M.; Kanazawa, I. Positive Symptoms in Multiple Sclerosis: Their Treatment with Sodium Channel Blockers, Lidocaine and Mexiletine. J. Neurol. Sci. 1999, 162, 162-168.
114. Jankovic, J. Parkinson's Disease: Clinical Features and Diagnosis. J. Neurol. Neurosurg. Psychiatr. 2008, 79, 368-376
115. Palop, J.; Thwin, M.; Ho, K.; Yu, G.; Mucke, L. P1-078: Alterations in Voltage-gated Sodium Channels in Transgenic Mouse Models of Alzheimer's Disease: Implications for Aß-Induced Network Dysfunction. Alzheimers Dement. 2008, 4, T229-T229.
116. Imarisio, S.; Carmichael, J.; Korolchuk, V.; Chen, C.-W.; Saiki, S.; Rose, C.; Krishna, G.; Davies, J.E.; Ttofi, E.; Underwood, B.R.; Rubinsztein, D.C. Huntington's Disease: From Pathology and Genetics to Potential Therapies. Biochem. J. 2008, 412, 191-209.
117. Oyama, F.; Miyazaki, H.; Sakamoto, N.; Becquet, C.; Machida, Y.; Kaneko, K.; Uchikawa, C.; Suzuki, T.; Kurosawa, M.; Ikeda, T.; Tamaoka, A.; Sakurai, T.; Nukina, N. Sodium Channel β4 Subunit: Down-regulation and Possible Involvement in Neuritic Degeneration in Huntington's Disease Transgenic Mice. J. Neurochem. 2006, 98, 518-529
118. Meisler, H.M.; Kearney, J.A. Sodium Channel Mutations in Epilepsy and Other Neurological Disorders. J. Clin. Invest. 2005, 115, 2010-2017.
119. Lenzenweger, M.F.; Lane, M.C.; Loranger, A.W.; Kessler, R.C. DSM-IV Personality Disorders in the National Comorbidity Survey Replication. Biol. Psychiat. 2007, 62, 553-564.
120. Tadić, A.; Baskaya, Ö.; Victor, A.; Lieb, K.; Höppner, W.; Dahmen N. Association Analysis of SCN9A Gene Variants with Borderline Personality Disorder. J. Psychiatric Res. 2009, 43, 155-163.
121. Trudeau, M.M.; Dalton, J.C.; Day, J.W.; Ranum, L.P.W.; Meisler, M.H. Heterozygosity for a Protein Truncation Mutation of Sodium Channel SCN8A in a Patient with Cerebellar Atrophy, Ataxia, and Mental Retardation J. Med. Genet. 2006, 43, 527-530.
122. Clare, J.J.; Tate, S.N.; Nobbs, M.; Romanos, M.A. Voltage-gated Sodium Channels as Therapeutic Targets. Drug Discov. Today 2000, 5, 506-520.
123. Vestergaard, K.; Andersen, G.; Gottrup, H.; Kristensen, B.T.; Jensen, T.S. Lamotrigine for Central Poststroke Pain: A Randomized Controlled Trial. Neurology 2001, 56, 184-190.
124. Fitton, A.; Goa, K.L. Lamotrigine. An Update of its Pharmacology and Therapeutic Use in Epilepsy. Drugs 1995, 50, 691-713.
125. Pappagallo, M. Newer Antiepileptic Drugs: Possible Uses in the Treatment of Neuropathic Pain and Migraine. Clin. Ther. 2003, 25, 2506-2538.
126. Kapoor, R. Sodium Channel Blockers and Neuroprotection in Multiple Sclerosis Using Lamotrigine. J. Neurol. Sci. 2008, 274, 54-56.
127. Leandri, M.; Lunari, G.; Inglese, M.; Messmer-Uccelli, M.; Mancardi, G.L.; Gottlieb, A.; Solaro, C. Lamotrigine in Trigeminal Neuralgia Secondary to Multiple Sclerosis. J. Neurol. 2000, 247, 556-558.
128. Bowden, C.L.; Mitchell, P.; Suppes, T. Lamotrigine in the Treatment of Bipolar Depression. Eur. Neuropsychopharm. 1999, 9, S113-S117.
129. Gabriel, A. Lamotrigine Adjunctive Treatment in Resistant Unipolar Depression: An Open, Descriptive Study. Depress. Anxiety 2006, 23, 485-488.
130. Shorvon, S. Oxcarbazepine: A Review. Seizure 2000, 9, 75-79.
131. Ambrosio, A.F.; Soares-Da-Silva, P.; Carvalho, C.M.; Carvalho, A.P. Mechanism of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIO 2-024. Neurochem. Res. 2002, 27, 121-130.
132. Schachter, S.C. Currently Available Antiepileptic Drugs. Neurotherapeutics 2007, 4, 4-11.
133. Popova, E.; Leighton, C.; Bernabarre, A.; Bernardo, M.; Vieta, E. Oxcarbazepine in the Treatment of Bipolar and Schizoaffective Disorders. Expert Rev. Neurother. 2007, 7, 617-626.
134. Colombo, E.; Curatolo, L.; Caccia, C.; Salvati, P.; Faravelli, A. Ralfinamide Acts through NMDA Receptor Complex: A Central Role for Chronic Pain Treatment. Eur. J. Pain 2007, 11, 152-153.
135. Fallace, M.J. Update on Pharmacotherapy Guidelines for Treatment of Neuropathic Pain. Curr. Pain Headache Rep. 2007, 11, 208-214.
136. Beyreuther, B.K.; Callizot, N.; Stohr, T. Antinociceptive Efficacy of Lacosamide in a Rat Model for Painful Diabetic Neuropathy. Eur. J. Pharmacol. 2006, 539, 64-70.
137. Beyreuther, B.K.; Callizot, N.; Brot, M.D.; Feldman, R.; Bain, S.C.; Stohr, T. Antinociceptive Efficacy of Lacosamide in Rat Models for Tumor- and Chemotherapy-induced Cancer Pain. Eur. J. Pharmacol. 2007, 565, 98-104.
138. Ilyin, V.I.; Pomonis, J.D.; Whiteside, G.T.; Harrison, J.E.; Pearson, M.S.; Mark, L.; Turchin, P.I.; Gottshall, S.; Carter, R.B.; Nguyen, P.; Hogenkamp, D.J.; Olanrewaju, S.; Benjamin, E.; Woodward, R.M. Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-spectrum State-dependent Sodium Channel Blocker for Treating Pain States. J. Pharmacol. Exp. Ther. 2006, 318, 1083-1093.
139. + Channel Blocker, in Experimental Animal Models of Inflammatory and Neuropathic Pain. Pain 2003, 102, 17-25.
140. Akada, Y.; Ogawa, S.; Amano, K.; Fukudome, Y.; Yamasaki, F.; Itoh, M.; Yamamoto, I. Potent Analgesic Effects of a Putative Sodium Channel Blocker M58373 on Formalin-induced and Neuropathic Pain in Rats. Eur. J. Pharmacol. 2006, 536, 248-255.
141. Brochu, R.M.; Dick, I.E.; Tarpley, J.M.; McGowan, E.; Gunner, D.; Herringon, J.; Shao, P.P.; Ok, D.; Li, C.; Parsone, W.H.; Stump, G.L.; Regan, C.P.; Lynch, Jr., J.J.; Lyons, K.A.; McManus, O.B.; Clark, S.; Ali, Z.; Kaczorowski, G.J.; Martin, W.J.; Priest, B.T. Block of Peripheral Nerve Sodium Channels Selectively Inhibits Features of Neuropathic Pain in Rats. Mol. Pharmacol. 2006 69, 823-832.
142. Shao, P.P.; Ok, D.; Fisher, M.H.; Garcia, M.L.; Kaczorowski, G.J.; Li, C.; Lyons, K.A.; Martin, W.J.; Meinke, P.T.; Priest, B.T.; Smith, M.M.; Wyvratt, M.J.; Ye, F.; Parsons, W.H. Novel Cyclopentane Dicarboxamide Sodium Channel Blockers as a Potential Treatment for Chronic Pain. Bioorg. Med. Chem. Lett. 2005, 15, 1901-1907.
143. Perucca, E. A Pharmacological and Clinical Review on Topiramate, a New Antiepileptic Drug. Pharmacol. Res. 1997, 3, 241-256.
144. Arain, A.M. Medical Therapy of Epilepsy. Expert Opin. Ther. Pat. 2007, 17, 955-964.
145. Welch, K.M. Brain hyperexcitability: The Basis for Antiepileptic Drugs in Migrain Prevention. Headache 2005, 45, 25-32
146. Murata, M.; Hasegawa, K.; Kanazawa, I. Zonisamide Improves Motor Function in Parkinson Disease. Neurology 2007, 68, 45-50.
147. Hakimian, S.; Cheng-Hakimian, A.; Anderson, G D.; Miller, J.W. Rufinamide: A New Anti-epileptic Medication. Expert Opin. Pharmacother. 2007, 8, 1931-1940.
148. Chung, A.M.; Eiland, L.S. Use of Second-generation Antiepileptic Drugs in the Pediatric Population. Paediatr. Drugs 2008, 10, 217-254.
149. Bialer, M.; Johannessen, S.I.; Kupferberg, H.J.; Levy, R.H.; Perucca, E.; Tomson, T. Progress Report on New Antiepileptic Drugs: A Summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004, 61, 1-48.
150. Rogawski, M.A. Diverse Mechanism of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2006, 69, 273-294.
151. Deshpande, L.S.; Nagarkatti, N.; Sombati, S.; DeLorenzo, R.J. The Novel Antiepileptic Drug Carisbamate (RWJ 333369) is Effective in Inhibiting Spontaneous Recurrent Seizure Discharges and Blocking Sustained Repetitive Firing in Cultured Hippocampal Neurons. Epilepsy Res. 2008, 79, 158-165.
152. Boyd, B.; Castaner, J. RWJ-333369. Antepileptic Drug, Treatment of Migraine. Drugs Future 2006, 31, 114-116.
153. Dupere, J.R.B.; Dale, T.J.; Starkey, S.J.; Xie, X. The Anticonvulsant BW534U87 Depresses Epileptiform Activity in Rat Hippocampal Slices by an Adenosine-Dependent Mechanism and Through Inhibition of Voltage-gated Na+ Channels. Br. J. Pharmacol. 1999, 128, 1011-1020.
154. Foreman, M.M.; Hanania, T.; Stratton, S.C.; Wilcox, K.S.; White, H.S.; Stables, J.P.; Eller, M. In Vivo Pharmacological Effects of JZP-4, a Novel Anticonvulsant, in Models for Anticonvulsant, Antimania and Antidepressant Activity. Pharmacol., Biochem. and Behav. 2008, 89, 523-534.
155. Abraham, S.; Jones, C.A.; Kirkpatrick, P. Ranolazine. Nat. Rev. Drug Discov. 2006, 5, 453-454.
156. Hale, S.L.; Shryock, J.C.; Belardinelli, L.; Sweeney, M.; Kloner, R.A. Late Sodium Current Inhibition as a New Cardioprotective Approach. J. Mol. Cell Card. 2008, 44, 954-967.
157. Na and Suppresses Early Afterdepolarizations and Torsades De Pointes Induced by Class III Agents. Cardiovasc. Res. 2006, 70, 486-496.
158. Roy, D.; Rowe, B.H.; Stiell, I.G.; Coutu, B.; Ip, J.H.; Phaneuf, D.; Lee, J.; Vidaillet, H.; Dickinson, G.; Grant, S.; Ezrin, A.M.; Beatch, G.N. A Randomized, Controlled Trial of RSD1235, a Novel Anti-arrhythmic Agent, in the Treatment of Recent Onset Atrial Fibrillation. J. Am. Coll. Cardiol. 2004, 44, 2355-2361.
159. Crijns, H.J.; Van Gelder, I.C.; Walfridsson, H.; Kulakowski, P.; Rónaszéki, A.; Dedek, V.; Malm, A.; Almgren, O. Safe and Effective Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009. Heart Rhythm 2006, 3, 1321-1331.
160. + Overload. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358, 547-553.
161. John, G.W.; Létienne, R.; Grand, B.; Pignier, C.; Vacher, B.; Patoiseau, J.-F.; Colpaert, F.C.; Coulombe, A. KC 12291: An Atypical Sodium Channel Blocker with Myocardial Antiischemic Properties. Cardiovasc. Drug. Rev. 2004, 22, 17-26.
162. Miller, R.G.; Mitchell, J.D.; Lyon, M.; Moore, D.H. Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND). Cochrane Database Syst. Rev. 2007, 1, 1-23.
163. Bezard, E.; Stutzmann, J.-M.; Imbert, C.; Boraud, T.; Boireau, A.; Gross, C.E. Riluzole Delayed Appearance of Parkinsonian Motor Abnormalities in a Chronic MPTP Monkey Model. Eur. J. Pharmacol. 1998, 356, 101-104.
164. Zarate, C.A. Jr.; Payne, J.L.; Quiroz, J.; Sporn, J.; Denicoff, K.K.; Luckenbaugh, D.; Charney, D.S.; Manji, H.K. An Open-label Trial of Riluzole in Patients with Treatment-resistant Major Depression. Am. J. Psychiatr. 2004, 161, 171-174.
165. Coric, V.; Taskiran, S.; Pittenger, C.; Wasylink, S.; Mathalon, D.H.; Valentine, G.; Saksa, J.; Wu, Y.T.; Gueorguieva, R.; Sanacora, G.; Malison, R.T.; Krystal, J.H. Riluzole Augmentation in Treatment-resistant Obsessive-compulsive Disorder: An Open-label Trial. Biol. Psychiatry 2005, 58, 424-428.